Here's the sentence that should have been on every front page on September 8, 2026, and wasn't:
Black women had the strongest protective effect.
That's the finding buried in the new JAMA Internal Medicine analysis of 20 years of SWAN data – the first US study of its kind to look at future cardiovascular events in women with hot flashes and night sweats who start hormone therapy in peri- or early postmenopause. And it's the piece of the HRT story that the women who most needed the 2002 correction have been waiting a generation to hear.
Let's walk the whole arc, because if you're over 45 you've been living inside it whether you know it or not.
The fear that wouldn't die
In 2002, the Women's Health Initiative reported increased heart risks in women taking combined estrogen-plus-progestin, and a generation internalized a three-word sentence: HRT causes heart attacks. Prescriptions collapsed – from roughly 27% of postmenopausal women in 1999 to under 5% by 2020 Established: Epic Research. Doctors learned to say no before the question finished. Women learned to stop asking.
The problem? The average WHI participant was in her 60s – a decade or more past menopause onset. The findings were real for that population, and they got applied to everyone Established: NPR.
Two decades of reanalysis later, the regulatory half of the correction landed: in November 2025, the FDA began removing the black-box cardiovascular warnings from hormone therapy, with Commissioner Dr. Marty Makary calling the WHI-era demonization "an American tragedy" Established: CBS News.
But here's what a label change can't do: it can't give a woman in a doctor's office the answer to "but is my heart safe on this?" That question needed data – US data, with the timing spelled out. It arrived September 8, 2026.
What the study actually found
Researchers from VCU and the University of Pittsburgh went into SWAN – the Study of Women's Health Across the Nation, the largest and longest observational study of the menopause transition in the US – and pulled 20 years of clinical data (1997–2017) on more than 2,700 women who reported vasomotor symptoms (hot flashes, night sweats) and had no prior cardiovascular events. They then emulated a series of hypothetical clinical trials comparing women who started hormone therapy against women who didn't Established: JAMA Internal Medicine via VCU Health.
The result: hormone therapy initiated in peri- or early postmenopause was linked to a 22% lower risk of cardiovascular disease events – stroke, heart attack, congestive heart failure, revascularization – compared with non-users.
And the two strongest effects were in:
- Black women.
- Women who started within 10 years of menopause onset.
That second point is the timing window finally getting its receipts. That first point is the one nobody's leading with – in a research landscape where Black women have been chronically under-studied, this is the largest US cohort data showing a group that has every reason to feel unseen by menopause medicine getting the strongest signal.
What this does NOT say
Read this part twice, because it's where the trust lives.
The study is observational – not a randomized controlled trial. Its own senior authors, Dr. Samar El Khoudary (VCU) and Dr. Rebecca Thurston (University of Pittsburgh), are explicit: the findings do not support using hormone therapy for cardiovascular disease prevention and should not guide clinical practice Established: JAMA Internal Medicine via VCU Health. Breast-cancer risk rises with longer duration of use. HRT is not a heart drug. It never was, and the pendulum swinging back doesn't make it one.
That's the same honesty bar that applies to the whole HRT comeback: it's much safer than the 2000s believed for women starting at the right time, and it is not the fountain of youth Established: NPR.
"But I'm 57. Am I too late?"
The sub-question hiding under every article about this study – is the window closed for me? – deserves a straight answer.
The strongest data here is for women starting in peri- or early postmenopause, within 10 years of onset. If you're past that, you're in the territory the WHI actually studied – the older starters whose risks drove the original scare. That doesn't mean you have no options; it means the risk-benefit math is genuinely different, and anyone who gives you a blanket "sure, start today" without talking about timing and your personal cardiovascular risk profile is overselling.
The right move isn't despair or a group-chat verdict. It's walking into the appointment with this study in your pocket and asking better questions – about your symptoms, your window, your blood pressure, your lipids, and what monitoring would look like. That's a conversation this data finally makes possible instead of the flat "no" of the last two decades.
The bottom line
The 2002 fear was overbroad. The FDA said so. The science now says so with 20 years of US data and a 22% number. The Black-women finding is the part worth screenshotting and sending – because being seen in the data is the first step to being seen in the exam room.
Take the hormone therapy for the hot flashes that are stealing your sleep and your sanity. Let the heart-attack fear retire. And keep the caveats close: this study answers a question. It doesn't write a prescription – and it shouldn't have to, for you to finally feel safe asking for one.